Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Breast Cancer Research

Fig. 2

From: Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

Fig. 2

Summary of toxicities. a Hematological toxicities: 12/27 (44%) had ≥ grade 3 hematological toxicity, including neutropenia (n = 10), lymphopenia (n = 6), and leukopenia (n = 7). b Non-hematologic toxicities: 9/27 (33%) had grade 3 non-hematological toxicity, including oral mucositis (n = 3), hyperglycemia (n = 3), and fatigue (n = 5). The counts of maximum ≥ grade 2 for each participant was listed for each event type (either ≥ grade 3 toxicity, or 2 participants experienced a grade 2 toxicity)

Back to article page